← Back to GANX

Gain Therapeutics, Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSJun 2026Filed 11/08/2026Mar 2026Filed 11/05/2026Sep 2025Filed 12/11/2025Jun 2025Filed 11/08/2026Mar 2025Filed 11/05/2026Sep 2024Filed 12/11/2025Jun 2024Filed 12/08/2025Mar 2024Filed 14/05/2025
−$4.7−$5.6−$5.3−$5.8−$4.5−$4.5−$8.1−$4
−$0.11−$0.13−$0.15−$0.19−$0.16−$0.17−$0.42−$0.22
4342353029271918

Trend

Net income

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.